335293-21-5

Upstream product

• 75-36-5 acetyl chloride 
• 199850-56-1 methyl 2-amino-4-chloro-5-iodobenzoate 

Downstream Products

• 335293-22-6 dimethyl 6-N-acetylamino-4-chloro-1,3-isophthalate 
• 335293-20-4 4-(2-(N-tert-butoxycarbonylazetidin-2(S)-yl)ethoxy)-7-chloro-2-oxo-3-(3,4,5-trimethylphenyl)-1,2-dihydroquinoline-6-carboxylic acid pyrimidin-4-ylamide 
• 335293-24-8 4-(2-(N-tert-butoxycarbonylazetidin-2(S)-yl)ethoxy)-7-chloro-2-oxo-3-(3,4,5-trimethylphenyl)-1,2-dihydoquinoline-6-carboxylic acid 
• 362604-16-8 dimethyl 6-N-(3,4,5-trimethylphenyl)acetylamino-4-chloro-1,3-isophthalate 
• 335293-17-9 6-carbomethoxy-7-chloro-4-hydroxy-3-(3,4,5-trimethylphenyl)-1H-quinolin-2-one 
• 335293-15-7 dimethyl 6-amino-4-chloro-1,3-isophthalate 

Relevant academic research and scientific papers

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor

Extensive development of the structure - activity relationships of a screening lead determined three important pharmacophores for gonadotropin-releasing hormone (GnRH) receptor antagonist activity. Incorporation of the 3,4,5-trimethylphenyl group at the 3